MEI Pharma: Double Trouble Or Double Double? [Seeking Alpha]
MEI Pharma, Inc. (MEIP)
Last mei pharma, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.meipharma.com
Company Research
Source: Seeking Alpha
Summary Quick Background: I am a Physician (Board Certified in Child Psychiatry, Adult Psychiatry, and General Pediatrics) and I have been an investor in individual biotech companies for about 5 years. I first published on Seeking Alpha in 2014 and have recently resumed writing here. My focus is finding value in Biotech companies while also reviewing technical aspects of their stocks. General Overview of MEI Pharma ( MEIP ): MEI Pharma is a mid-stage biotech company that is devoted to cancer therapy research. They currently have 3 compounds in their pipeline. The first of these is Pracinostat, an oral histone deacetylase (HDAC) inhibitor, which is being investigated as combo therapy for Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis. The second is ME-401, a PI3K Delta inhibitor, which is being investigated as single agent therapy for Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). Finally, there is ME-344, a mitochondri
Show less
Read more
Impact Snapshot
Event Time:
MEIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEIP alerts
High impacting MEI Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
MEIP
News
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.MarketBeat
- MEI Pharma shelves plans for a second return of capital [Seeking Alpha]Seeking Alpha
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]Yahoo! Finance
MEIP
Earnings
- 2/13/24 - Miss
MEIP
Sec Filings
- 2/29/24 - Form EFFECT
- 2/28/24 - Form 424B5
- 2/21/24 - Form 8-K
- MEIP's page on the SEC website